Scientists from the University of Helinski have found a new molecule that could possibly treat Parkinson’s disease. This may be a potential breakthrough in forming the therapeutics for neurodegenerative diseases.
Parkinson is a slow degenerative neurological disorder that affects a wide range of people on a global scale. It is seen that elderly people are more affected by this disorder. Currently, one or two medications are on the roll to support the disorder. However, such medications are not proven to completely cure the disease. Therefore, new medications and innovative therapies are in need to treat this condition. This has led researchers from the University of Helsinki to find a new molecule. The new molecule, going by the name BT13, has proven effective when compared to the current medications treating the disorder. Therefore, this therapy may form the basis of future treatment for treating the disorder.
The potential keyhole
Parkinson’s results when there is death in the basal ganglia, producing dopamine in the Substantia Nigra of the brain. This leads to lower levels of circulating dopamine in neurons, leading to motor incoordination. Thus, current therapy is based on compensating for the levels of dopamine in the body. But the dopamine, which is taken in the oral form, is not able to cross the blood-brain barrier. Thus, different therapies are the roll to find an alternative solution. One such therapy was on the focus was Glial Cell Derived Neurotrophic Factor (GDNF) that will able to heal the damaged glial cells. But this procedure requires a compact surgery for transferring the molecule right into the brain. Also, it did not give effective results in clinical trials.
But the new molecule BT13 is indeed capable of stimulating the production of dopamine in the brains of mice. In addition to this, it is also able to protect the cells that produce dopamine from lysis. But the most important part is that this molecule is effectively able to pass the blood-brain barrier. With innovative research on this molecule and further clinical trials, we may be able to treat this disorder in humans effectively in the future.
Join our writing team and develop your writing skills, as you see your articles featured on Apple News, Google News, and all around the world. Subscribe to our newsletter, What Just Happened, where we dive deep into the hottest topics from the week!